COLGATE TOTAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Colgate Total, and when can generic versions of Colgate Total launch?
Colgate Total is a drug marketed by Colgate Palmolive and is included in one NDA.
The generic ingredient in COLGATE TOTAL is sodium fluoride; triclosan. There are one thousand four hundred and seventy-two drug master file entries for this compound. Additional details are available on the sodium fluoride; triclosan profile page.
Summary for COLGATE TOTAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 30 |
| Patent Applications: | 413 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | COLGATE TOTAL at DailyMed |
Recent Clinical Trials for COLGATE TOTAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Baghdad | Phase 3 |
| University of California, San Francisco | Early Phase 1 |
| Liverpool University Hospitals NHS Foundation Trust | Phase 4 |
Anatomical Therapeutic Chemical (ATC) Classes for COLGATE TOTAL
US Patents and Regulatory Information for COLGATE TOTAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for COLGATE TOTAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| Colgate Palmolive | COLGATE TOTAL | sodium fluoride; triclosan | PASTE;DENTAL | 020231-001 | Jul 11, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for COLGATE TOTAL
See the table below for patents covering COLGATE TOTAL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Finland | 97329 | ⤷ Try a Trial | |
| Norway | 178953 | ⤷ Try a Trial | |
| New Zealand | 238146 | DENTIFRICE COMPOSITION INCLUDING AN ALKALI METAL OR AMMONIUM PHOSPHATE SALT AND A WATER INSOLUBLE NON CATIONIC ANTIBACTERIAL AGENT | ⤷ Try a Trial |
| Slovakia | 280567 | ⤷ Try a Trial | |
| Australia | 640355 | ⤷ Try a Trial | |
| China | 1044047 | ⤷ Try a Trial | |
| Norway | 301214 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for COLGATE TOTAL
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2822954 | LUC00083 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625 |
| 0268956 | 1999C0030 | Belgium | ⤷ Try a Trial | PRODUCT NAME: RABEPRAZOLE SODIUM; NAT. REGISTRATION NO/DATE: 5532 IE 1 F 3 19990201; FIRST REGISTRATION: GB 10555/0010 19980508 |
| 0473687 | SPC/GB98/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| 2666774 | CA 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 1912999 | 1490062-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 2666774 | CR 2020 00037 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217 |
| 3141251 | 301099 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
